44 results about "Cathepsin Y" patented technology

This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

The present invention is directed to novel cyanoalkylamino derivatives that are inhibitors of cysteine protease such as cathepsins K, S, B and L, in particular cathepsin K Pharmaceutical composition comprising these compounds, method of treating diseases mediated by unregulated cysteine protease activity, in particular cathepsin K utilizing these compounds and methods of preparing these compounds are also disclosed.

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

Method of diagnosing persistent, chronic synovitis and progressive joint degradation in the joint of a mammal. The method including providing a test sample comprising synovial fluid, cell or tissue from the joint of a mammal; detecting the presence of bacterial DNA, measuring the concentration of one or more biomarkers being cathepsin K, MMP-2 and -9, cathepsin S, tartrate-resistant acid phosphatase, invariant chain, CD4+ T-lymphocytes, CD8+ T-lymphocytes, CD44+ mononuclear cells, Toll-like receptor-2, Toll-like receptor-9, or a combination thereof; and, comparing the concentration of the biomarker from the test sample to a corresponding biomarker concentration in a control sample from healthy dogs, or an internal PBMC control sample, wherein a statistically significant elevated concentration of the biomarker in the test sample indicates that the mammal's joint is diseased.

This invention relates to compounds of formula (I) which are cysteine protease inhibitors, in particular, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

This invention relates to a novel class of compounds, represented by the formula (I) below, wherein the meanings of R1, R2, R3 and R4 are indicated therein, which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis, osteoarthritis and rheumatoid arthritis.

Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (Ia) and (Ib) where R1, R2, R3, R4, R5, R6, R8, R9 and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds

Disclosed are cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (Ia) and (Ib) where R2, R3, R4, R6, R8 and Y are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds

The invention discloses a making method of preconditioned shelled Penaeus vannamei Boone. The method comprises the following steps: removing heads, shells and digestive tracts from fresh Penaeus vannamei Boone, and washing and draining the Penaeus vannamei, or unfreezing frozen shelled Penaeus vannamei Boone at room temperature to obtain unfrozen shelled Penaeus vannamei Boone for later use; preparing a preconditioning preserving liquid; uniformly mixing the shelled Penaeus vannamei Boone with the preserving liquid; placing the obtained shelled Penaeus vannamei Boone and preserving liquid mixture in a vacuum rolling machine, and rolling the mixture; taking out the rolled shelled Penaeus vannamei Boone, and carrying out vacuum packaging; and carrying out freezing storage or refrigeration on the packaged shelled Penaeus vannamei Boone. Food grade components contained in the preconditioning preserving liquid can effectively inhibit tissue protease and microorganisms of the shelled Penaeus vannamei Boone in the processing process and prevent proteolysis and microbial propagation induced quality reduction, and the rolling preserving increases the muscle elasticity of the shelled Penaeus vannamei Boone and increases the preserving efficiency.

The present invention relates to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

of the formula (IV): where: R1=R'C(O), R'SO2, R'=a bicyclic, saturated or unsaturated, 8-12 membered ring system containing 0-4 hetero atoms selected from S, O and N, which is optionally substituted with up to four substituents independently selected from groups a), b) and c) below; or R'=a monocyclic, saturated or unsaturated, 5-7 membered ring containing 0-3 hetero atoms selected from S, O and N, which monocyclic ring bears at least one substituent selected from group a) and / or c) and which may optionally bear one or two further substituents selected from group b); R4=H, C1-7-alkyl, Ar-C1-7-alkyl, Ar, C3-7-cycloalkyl; C2-7alkenyl; R3=C1-7-alkyl, C2-C7 alkenyl, C2-C7 alkenyl, C3-7-cycloalkyl, Ar-C1-7-alkyl, Ar; R5=C1-7-alkyl, halogen, Ar-C1-7-alkyl, C1-3-alkyl-CONR3R4 or a bulky amine R6 is H, C1-7-alkyl, Ar-C1-7-alkyl, C1-3-alkyl-SO2-R<ix>, C1-3-alkyl-C(O)-NHR<ix >or CH2XAr q is 0 or 1 have utility as inhibitors of cysteine proteases such as cathepsin K and falcipain.

Novel inhibitors of cathepsin S, K, B, and L, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.

The invention belongs to the technical field of cultivation of Cordyceps militaris, in particular to a method for cultivating selenium-enriched Cordyceps militaris. According to the method for cultivating the selenium-enriched Cordyceps militaris, a strain activation culture medium, a seed liquid culture medium and a liquid fermentation medium are carefully screened, molasses, sucrose, peptone, radix astragali, yeast selenium, radish, Enteromorpha residue, egg white, potassium dihydrogen phosphate and magnesium sulfate are taken as main nutrient raw materials, and cathepsin and cellulase are added, so that dissolution and absorption of various raw materials are facilitated; and added EDTA-4Na also contributes to transfer and absorption of selenium. Furthermore, in the method of the presentinvention, the content of selenium in mycelia of Cordyceps militaris is further increased by adding amino acid chelated calcium to the fermentation medium to better induce absorption and accumulationof selenium.

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them. The present invention is also directed to the use of these inhibitors in combination with a therapy that causes a deleterious immune response in patients receiving the therapy.

The present invention relates to compounds substituted by haloalkyl of the following formula (I), wherein R 7 Represents haloalkyl, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 8 The definition is the same as the claims. The compounds are inhibitors of cysteine ​​proteases, especially cathepsins B, K, L, F and S, and are therefore useful in the treatment of diseases mediated by these proteases. The invention also discloses pharmaceutical compositions including these compounds and their references.

Disclosed are novel nitrile compounds of formula (I) further defined herein, which compounds are useful as reversible inhibitors of cysteine proteases such as cathepsin K, S, F, L and B. These compounds are useful for treating diseases and pathological conditions exacerbated by these proteases such as, but not limited to, osteoporosis, rheumatoid arthritis, multiple sclerosis, asthma and other autoimmune diseases, Alzheimer's disease, atherosclerosis. Also disclosed are processes for making such novel compounds.

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

The present invention is directed to compounds that are inhibitors of cysteine protease, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S, and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.